Phase 1 Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BMS-906024 in Subjects With Advanced Solid Tumors

Inclusion Criteria:

- Subjects with advanced or metastatic solid tumors (non-hematologic) refractory to or
relapsed from standard therapies or for which there is no know effective treatment
during dose escalation.

- Subjects with colorectal cancer, non-small cell lung cancer, triple-negative breast
or other solid tumor types for which Notch activation has been demonstrated (such as
pancreatic, ovarian and melanoma) during dose expansion

- Biopsy accessible tumor (may be waived under certain circumstances)

- Life expectancy of at least 3 months

- Eastern Cooperative Oncology Group (ECOG) 0-1

- Adequate organ and bone marrow function

Exclusion Criteria:

- Infection

- Elevated triglycerides

- Gastrointestinal (GI) disease with increased risk of diarrhea (e.g. inflammatory
bowel disease (IBD))

- Taking medications known to increase risk of Torsades De Pointes